TY - JOUR
T1 - IL-6, calcium, salivary amylase activity and cortisol as a salivary biomarker-combination associated with obesity
T2 - a pilot study
AU - Al Habobe, H
AU - Haverkort, E B
AU - Nazmi, K
AU - Van Nieukerken, L K
AU - Gerdes, V E A
AU - Bikker, F J
AU - Pieters, R H H
N1 - © 2026 Al Habobe, Haverkort, Nazmi, Van Nieukerken, Gerdes, Bikker and Pieters.
PY - 2025
Y1 - 2025
N2 - INTRODUCTION: As obesity continues to escalate to pandemic levels worldwide, innovative approaches for early diagnosis, risk stratification, and disease monitoring are urgently needed. Saliva presents a promising non-invasive method for biomarker-based screening in obesity.OBJECTIVE: This study aimed to utilize a multi-biomarker approach to explore associations between salivary biomarkers and obesity. This was done by measuring a pre-selected panel of obesity-related salivary biomarkers and comparing their levels between individuals with and without obesity.METHODS: Unstimulated saliva was collected from 57 individuals, including 27 individuals diagnosed with obesity (BMI ≥ 30 kg/m
2) and 30 non-obese controls (BMI < 30 kg/m
2). Various biochemical techniques were used to quantify salivary total protein content,
α-amylase activity (sAA), cortisol, interleukin 6 (IL-6), mucin 5B (MUC5B), albumin and calcium ions (Ca
2+).
RESULTS: The results indicated lower Ca
2+, sAA, and MUC5B levels (
P < 0.05) and higher IL-6 and cortisol levels (
P < 0.05) in the obese group compared to non-obese controls. In the obese group, Ca
2+ correlated positively with most biomarkers, with sAA (r = 0.632,
P < 0.05) and IL-6 (r = 0.449,
P < 0.05) showing the strongest associations.
CONCLUSIONS: In conclusion, this study highlights IL-6, Ca
2+, sAA, and cortisol as a potential salivary biomarker-combination associated with obesity warranting further investigation. The observed changes in the salivary biomarker levels of the obese group may reflect underlying metabolic dysregulations, highlighting the advantage of a multi-biomarker approach to better capture early metabolic and inflammatory processes associated with obesity. To further validate these findings, large clinical studies with diverse, well-matched cohorts, as well as longitudinal studies, are needed.
AB - INTRODUCTION: As obesity continues to escalate to pandemic levels worldwide, innovative approaches for early diagnosis, risk stratification, and disease monitoring are urgently needed. Saliva presents a promising non-invasive method for biomarker-based screening in obesity.OBJECTIVE: This study aimed to utilize a multi-biomarker approach to explore associations between salivary biomarkers and obesity. This was done by measuring a pre-selected panel of obesity-related salivary biomarkers and comparing their levels between individuals with and without obesity.METHODS: Unstimulated saliva was collected from 57 individuals, including 27 individuals diagnosed with obesity (BMI ≥ 30 kg/m
2) and 30 non-obese controls (BMI < 30 kg/m
2). Various biochemical techniques were used to quantify salivary total protein content,
α-amylase activity (sAA), cortisol, interleukin 6 (IL-6), mucin 5B (MUC5B), albumin and calcium ions (Ca
2+).
RESULTS: The results indicated lower Ca
2+, sAA, and MUC5B levels (
P < 0.05) and higher IL-6 and cortisol levels (
P < 0.05) in the obese group compared to non-obese controls. In the obese group, Ca
2+ correlated positively with most biomarkers, with sAA (r = 0.632,
P < 0.05) and IL-6 (r = 0.449,
P < 0.05) showing the strongest associations.
CONCLUSIONS: In conclusion, this study highlights IL-6, Ca
2+, sAA, and cortisol as a potential salivary biomarker-combination associated with obesity warranting further investigation. The observed changes in the salivary biomarker levels of the obese group may reflect underlying metabolic dysregulations, highlighting the advantage of a multi-biomarker approach to better capture early metabolic and inflammatory processes associated with obesity. To further validate these findings, large clinical studies with diverse, well-matched cohorts, as well as longitudinal studies, are needed.
U2 - 10.3389/fdmed.2025.1725865
DO - 10.3389/fdmed.2025.1725865
M3 - Article
C2 - 41584074
SN - 2673-4915
VL - 6
JO - Frontiers in Dental Medicine
JF - Frontiers in Dental Medicine
M1 - 1725865
ER -